TY  - JOUR
A1  - Dischinger, Ulrich
A1  - Hasinger, Julia
A1  - Königsrainer, Malina
A1  - Corteville, Carolin
A1  - Otto, Christoph
A1  - Fassnacht, Martin
A1  - Hankir, Mohamed
A1  - Seyfried, Florian Johannes David
T1  - Toward a Medical Gastric Bypass: Chronic Feeding Studies With Liraglutide + PYY\(_{3-36}\) Combination Therapy in Diet-Induced Obese Rats
JF  - Frontiers in Endocrinology
N2  - Background
Combination therapies of anorectic gut hormones partially mimic the beneficial effects of bariatric surgery. Thus far, the effects of a combined chronic systemic administration of Glucagon-like peptide-1 (GLP-1) and peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) have not been directly compared to Roux-en-Y gastric bypass (RYGB) in a standardized experimental setting.


Methods
High-fat diet (HFD)-induced obese male Wistar rats were randomized into six treatment groups: (1) RYGB, (2) sham-operation (shams), (3) liraglutide, (4) PYY\(_{3-36}\), (5) PYY\(_{3-36}\)+liraglutide (6), saline. Animals were kept on a free choice high- and low-fat diet. Food intake, preference, and body weight were measured daily for 4 weeks. Open field (OP) and elevated plus maze (EPM) tests were performed.


Results
RYGB reduced food intake and achieved sustained weight loss. Combined PYY\(_{3-36}\)+liraglutide treatment led to similar and plateaued weight loss compared to RYGB. Combined PYY\(_{3-36}\)+liraglutide treatment was superior to PYY\(_{3-36}\) (p ≤ 0.0001) and liraglutide (p ≤ 0.05 or p ≤ 0.01) mono-therapy. PYY\(_{3-36}\)+liraglutide treatment and RYGB also reduced overall food intake and (less pronounced) high-fat preference compared to controls. The animals showed no signs of abnormal behavior in OF or EPM.


Conclusions
Liraglutide and PYY\(_{3-36}\) combination therapy vastly mimics reduced food intake, food choice and weight reducing benefits of RYGB.
KW  - obesity
KW  - rygb
KW  - liraglutide
KW  - peptide tyrosine tyrosine (PYY)
KW  - treatment
KW  - gastric bypass
KW  - peptide tyrosine tyrosine 3-36 (PYY3-36)
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-223113
SN  - 1664-2392
VL  - 11
ER  - 
TY  - JOUR
A1  - Dischinger, Ulrich
A1  - Heckel, Tobias
A1  - Bischler, Thorsten
A1  - Hasinger, Julia
A1  - Königsrainer, Malina
A1  - Schmitt-Böhrer, Angelika
A1  - Otto, Christoph
A1  - Fassnacht, Martin
A1  - Seyfried, Florian
A1  - Hankir, Mohammed Khair
T1  - Roux-en-Y gastric bypass and caloric restriction but not gut hormone-based treatments profoundly impact the hypothalamic transcriptome in obese rats
JF  - Nutrients
N2  - Background: The hypothalamus is an important brain region for the regulation of energy balance. Roux-en-Y gastric bypass (RYGB) surgery and gut hormone-based treatments are known to reduce body weight, but their effects on hypothalamic gene expression and signaling pathways are poorly studied. Methods: Diet-induced obese male Wistar rats were randomized into the following groups: RYGB, sham operation, sham + body weight-matched (BWM) to the RYGB group, osmotic minipump delivering PYY3-36 (0.1 mg/kg/day), liraglutide s.c. (0.4 mg/kg/day), PYY3-36 + liraglutide, and saline. All groups (except BWM) were kept on a free choice of high- and low-fat diets. Four weeks after interventions, hypothalami were collected for RNA sequencing. Results: While rats in the RYGB, BWM, and PYY3-36 + liraglutide groups had comparable reductions in body weight, only RYGB and BWM treatment had a major impact on hypothalamic gene expression. In these groups, hypothalamic leptin receptor expression as well as the JAK–STAT, PI3K-Akt, and AMPK signaling pathways were upregulated. No significant changes could be detected in PYY3-36 + liraglutide-, liraglutide-, and PYY-treated groups. Conclusions: Despite causing similar body weight changes compared to RYGB and BWM, PYY3-36 + liraglutide treatment does not impact hypothalamic gene expression. Whether this striking difference is favorable or unfavorable to metabolic health in the long term requires further investigation.
KW  - obesity
KW  - Roux-en-Y gastric bypass surgery
KW  - liraglutide
KW  - PYY3-36
KW  - hypothalamic gene expression
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-252392
SN  - 2072-6643
VL  - 14
IS  - 1
ER  - 
TY  - JOUR
A1  - Trujillo‐Viera, Jonathan
A1  - El‐Merahbi, Rabih
A1  - Schmidt, Vanessa
A1  - Karwen, Till
A1  - Loza‐Valdes, Angel
A1  - Strohmeyer, Akim
A1  - Reuter, Saskia
A1  - Noh, Minhee
A1  - Wit, Magdalena
A1  - Hawro, Izabela
A1  - Mocek, Sabine
A1  - Fey, Christina
A1  - Mayer, Alexander E.
A1  - Löffler, Mona C.
A1  - Wilhelmi, Ilka
A1  - Metzger, Marco
A1  - Ishikawa, Eri
A1  - Yamasaki, Sho
A1  - Rau, Monika
A1  - Geier, Andreas
A1  - Hankir, Mohammed
A1  - Seyfried, Florian
A1  - Klingenspor, Martin
A1  - Sumara, Grzegorz
T1  - Protein Kinase D2 drives chylomicron‐mediated lipid transport in the intestine and promotes obesity
JF  - EMBO Molecular Medicine
N2  - Lipids are the most energy‐dense components of the diet, and their overconsumption promotes obesity and diabetes. Dietary fat content has been linked to the lipid processing activity by the intestine and its overall capacity to absorb triglycerides (TG). However, the signaling cascades driving intestinal lipid absorption in response to elevated dietary fat are largely unknown. Here, we describe an unexpected role of the protein kinase D2 (PKD2) in lipid homeostasis. We demonstrate that PKD2 activity promotes chylomicron‐mediated TG transfer in enterocytes. PKD2 increases chylomicron size to enhance the TG secretion on the basolateral side of the mouse and human enterocytes, which is associated with decreased abundance of APOA4. PKD2 activation in intestine also correlates positively with circulating TG in obese human patients. Importantly, deletion, inactivation, or inhibition of PKD2 ameliorates high‐fat diet‐induced obesity and diabetes and improves gut microbiota profile in mice. Taken together, our findings suggest that PKD2 represents a key signaling node promoting dietary fat absorption and may serve as an attractive target for the treatment of obesity.
KW  - chylomicron
KW  - fat absorption
KW  - intestine
KW  - obesity
KW  - protein kinase D2/PKD2/PRKD2
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-239018
VL  - 13
IS  - 5
ER  - 
TY  - THES
A1  - Schlör, Ute
T1  - PPARgamma-Polymorphismus (Pro12Ala)
T1  - PPARgamma polymorphism (Pro12Ala): A molecular marker to predict the loss of weight for patients with gastric banding operation
N2  - Es handelt sich um eine retrospektive klinische Studie, bei der wir den Einfluss der relativ häufig auftretenden Pro 12 Ala Mutation in PPARgamma auf das Körpergewichtund den Gewichtsverlauf nach gastric banding Operationen untersucht haben. Weiter untersuchten wir Parameter des Glukosestoffwechsels (Glukose, Insulin, C-Peptid). PPARs sind transkriptionelle Regulatoren der Genexpression in Glukose- und Lipidstoffwechsel und nehmen eine zentrale Rolle in der Regulation der Adipogenese und der Insulinsensitivität ein. Sie stellen ein Kandidatengen für Adipositas dar. Ziel war es, festzustellen, ob dieser Polymorphismus als molekularer Marker zur Vorhersage des Gewichtsverlaufes nach Magenbandoperation dienen kann. Das Patientengut besteht aus 62 Patienten, davon sind 30,65 % heterozygote Mutationsträger. Es ließ sich eine deutliche Assoziation dieses Pro12Ala Polymorphismus mit Adipositas feststellen und weiterhin, daß v.a. weibliche Mutationsträger signifikant schlechter an Gewicht abnehmen. Da ein Zusammenhang zwischen erhöhtem Insulinspiegel mit Fettspeicherung und somit mit Adipositas besteht, verglichen wir in den beiden untersuchten Gruppen die Insulinwerte. Bei den homozygot negativen Personen stellten wir eine Hyperinsulinämie fest, welche auf eine Insulinresistenz hindeuten könnte. Im Gegensatz dazu haben die Pro12Ala Mutationsträger Normwerte für Insulin, welches für eine verbesserte Insulinsensitivität spricht. Durch die signifikanten Ergebnisse ist es warscheinlich, daß dieser Polymorphismus als molekularer Marker neben internistischer, psychologischer und chirurgischer Voruntersuchung möglicherweise als Entscheidungshilfe dienen könnte.
N2  - PPARgamma is a nuclear receptor that regulates adipocyte differentiation and possibly lipid metabolism and insulin sensitivity. In this study we examined the role of Pro12Ala polymorphism in PPARgamma gene for body weight, bmi, weight loss and further the relationship to insulinsensitivity from patients who had a gastric banding operation. We took the data pre-operation, after 3 and 6 month. We saw that the Pro12Ala substitution in PPARgamma is associated we a worse weight loss after gastric banding operation and further improved insulinsensitivity. So it is possible that Pro12Ala polymorphism could be in combination with examinations of internits, psychologists and surgeons a molecular marker to predict the loss of weight for patients with gastric banding operation.
KW  - Adipositas
KW  - Insulinsensitivität
KW  - Magenbandoperation
KW  - gastric banding operation
KW  - insulinsensitivity
KW  - obesity
Y1  - 2002
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-4079
ER  - 
TY  - JOUR
A1  - Metzner, Valentin
A1  - Herzog, Gloria
A1  - Heckel, Tobias
A1  - Bischler, Thorsten
A1  - Hasinger, Julia
A1  - Otto, Christoph
A1  - Fassnacht, Martin
A1  - Geier, Andreas
A1  - Seyfried, Florian
A1  - Dischinger, Ulrich
T1  - Liraglutide + PYY\(_{3-36}\) combination therapy mimics effects of Roux-en-Y bypass on early NAFLD whilst lacking-behind in metabolic improvements
JF  - Journal of Clinical Medicine
N2  - Background: Treatment options for NAFLD are still limited. Bariatric surgery, such as Roux-en-Y gastric bypass (RYGB), has been shown to improve metabolic and histologic markers of NAFLD. Glucagon-like-peptide-1 (GLP-1) analogues lead to improvements in phase 2 clinical trials. We directly compared the effects of RYGB with a treatment using liraglutide and/or peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) in a rat model for early NAFLD. Methods: Obese male Wistar rats (high-fat diet (HFD)-induced) were randomized into the following treatment groups: RYGB, sham-operation (sham), liraglutide (0.4 mg/kg/day), PYY\(_{3-36}\) (0.1 mg/kg/day), liraglutide+PYY\(_{3-36}\), and saline. After an observation period of 4 weeks, liver samples were histologically evaluated, ELISAs and RNA sequencing + RT-qPCRs were performed. Results: RYGB and liraglutide+PYY\(_{3-36}\) induced a similar body weight loss and, compared to sham/saline, marked histological improvements with significantly less steatosis. However, only RYGB induced significant metabolic improvements (e.g., adiponectin/leptin ratio 18.8 ± 11.8 vs. 2.4 ± 1.2 in liraglutide+PYY\(_{3-36}\)- or 1.4 ± 0.9 in sham-treated rats). Furthermore, RNA sequencing revealed a high number of differentially regulated genes in RYGB treated animals only. Conclusions: The combination therapy of liraglutide+PYY\(_{3-36}\) partly mimics the positive effects of RYGB on weight reduction and on hepatic steatosis, while its effects on metabolic function lack behind RYGB.
KW  - liraglutide
KW  - GLP-1
KW  - peptide tyrosine tyrosine (PYY)
KW  - peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\))
KW  - RYGB
KW  - gastric bypass
KW  - obesity
KW  - NASH
KW  - NAFLD
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-255244
SN  - 2077-0383
VL  - 11
IS  - 3
ER  - 
TY  - THES
A1  - Stingl, Maria-Theresa
T1  - Kurz- und Langzeitergebnisse des laparoskopischen Gastric Banding (eine retrospektive Studie an 127 Patienten)
T1  - Short and long-term results of laparoscopic gastric banding (a retrospective study of 127 patients)
N2  - Die laparoskopische Implantation eines Magenbandes gilt als etabliertes Verfahren der bariatrischen Chirurgie. Im Rahmen der vorliegenden retrospektiven Studie an 127 Patienten wurden die Kurz- und Langzeitergebnisse des Laparoskopischen Gastric Banding (LAGB) untersucht. 60 Patienten wurden in Pergastrischer Technik, 67 Patienten in Pars flaccida Technik operiert. Untersucht wurde Sicherheit, Effizienz und Qualität des LAGB insbesondere im Hinblick auf die Art der angewandten Operationstechnik. Die mittlere Nachbeobachtungszeit betrug 63 Monate. Der mittlere prozentuale Übergewichtsverlust (EBWL %) war 50,6 %. Bei 39 Patienten traten ein oder mehrere Komplikationen auf. Die häufigsten Komplikationen waren Slippage und Pouchdilatation. Die Mortalitätsrate lag bei 0 %. Über 2/3 der Patienten dokumentierten eine Steigerung der subjektiven Lebensqualität durch das LAGB. Im Vergleich der Ergebnisse zweier verschiedener Operationstechniken stellte sich heraus, dass die Wahl des operativen Zugangsweges weder einen Einfluss auf die Effektivität der Gewichtsabnahme noch auf die Reduktion der körpergewichtsbedingten Komorbidität hat. In Übereinstimmung mit Ergebnissen anderer Studien zeigten sich Vorteile der Pars flaccida Technik im Sinne einer niedrigeren postoperativen Komplikationsrate. Insbesondere die sehr häufigen Komplikationen Pouchdilatation und Slippage traten in der Pars flaccida Gruppe signifikant seltener auf als bei den Patienten, die in Pergastrischer Technik operiert wurden. Zur Erhöhung der Effizienz sowie Reduktion der Komplikationsrate des LAGB ist - über die Optimierung operativ-technischer Aspekte hinaus- eine professionelle, interdisziplinäre und langfristige Nachbetreuung der Patienten unabdingbar.
N2  - The Laparoscopic Adjustable Gastric Banding (LAGB) has become a common bariatric procedure. Within this study 127 patients were analysed retrospectively after LAGB in terms of preoperative characteristics, weight loss, co-morbidities, short and long-term complications and quality of life. 60 patients were operated using the pergastric pathway (PG), 67 patients were operated using the pars flaccida technique (PF). The median follow-up was 63 month. Mean excess body weight loss (EBWL %) was 50.6 %. 39 patients experienced one ore more postoperative complications. The most frequent complications were slippage and pouch dilatation (34 %). Mortality rate was 0 %. Two-thirds of the patients reported an increase in quality of life after LAGB. Comparing the two different operation techniques (PF and PG-technique) there was no difference in weight loss or reduction of co-morbidities. In accordance with similar studies we documented a lower postoperative complication rate in the pars flaccida group. Especially the very frequent complications slippage and pouch dilatation occurred significantly less often using the pars flaccida technique.
KW  - Gastric-banding
KW  - Fettsucht
KW  - Langenbecks Archiv für Chirurgie
KW  - Diabetes mellitus
KW  - Gewichtsverlust
KW  - Minimal-invasive Chirurgie
KW  - Bariatrische Chirurgie
KW  - Laparoscopic adjustable Gastric Banding
KW  - Pars flaccida
KW  - Pergastrische Technik
KW  - Slippage
KW  - Pouchdilatation
KW  - bariatric surgery
KW  - obesity
KW  - Laparoscopic adjustable gastric banding
KW  - Pars flaccida
KW  - Pergastric technique
KW  - weight loss
KW  - Slippage
KW  - Pouchdilatation
Y1  - 2009
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-38672
ER  - 
TY  - JOUR
A1  - Hering, Ilona
A1  - Dörries, Luise
A1  - Flemming, Sven
A1  - Krietenstein, Laura
A1  - Koschker, Ann-Kathrin
A1  - Fassnacht, Martin
A1  - Germer, Christoph-Thomas
A1  - Hankir, Mohammed K.
A1  - Seyfried, Florian
T1  - Impact of preoperative weight loss achieved by gastric balloon on peri- and postoperative outcomes of bariatric surgery in super-obese patients: a retrospective matched-pair analysis
JF  - Langenbeck’s Archives of Surgery
N2  - Background
An intragastric balloon is used to cause weight loss in super-obese patients (BMI > 60 kg/m\(^2\)) prior to bariatric surgery. Whether weight loss from intragastric balloon influences that from bariatric surgery is poorly studied.

Methods
In this retrospective, single-center study, the effects of intragastric balloon in 26 patients (BMI 69.26 ± 6.81) on weight loss after bariatric surgery (primary endpoint), postoperative complications within 30 days, hospital readmission, operation time, and MTL30 (secondary endpoints) were evaluated. Fifty-two matched-pair patients without intragastric balloon prior to bariatric surgery were used as controls.

Results
Intragastric balloon resulted in a weight loss of 17.3 ± 14.1 kg (BMI 5.75 ± 4.66 kg/m\(^2\)) with a nadir after 5 months. Surgical and postoperative outcomes including complications were comparable between both groups. Total weight loss was similar in both groups (29.0% vs. 32.2%, p = 0.362). Direct postoperative weight loss was more pronounced in the control group compared to the gastric balloon group (29.16 ± 7.53% vs 23.78 ± 9.89% after 1 year, p < 0.05 and 32.13 ± 10.5% vs 22.21 ± 10.9% after 2 years, p < 0.05), who experienced an earlier nadir and started to regain weight during the follow-up.

Conclusion
A multi-stage therapeutic approach with gastric balloon prior to bariatric surgery in super-obese patients may be effective to facilitate safe surgery. However, with the gastric balloon, pre-treated patients experienced an attenuated postoperative weight loss with an earlier nadir and earlier body weight regain. This should be considered when choosing the appropriate therapeutic regime and managing patients’ expectations.
KW  - obesity
KW  - super-obesity
KW  - intragastric balloon
KW  - sleeve gastrectomy
KW  - Roux-en-Y gastric bypass
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-323909
VL  - 407
IS  - 5
ER  - 
TY  - JOUR
A1  - Plassmeier, Lars
A1  - Hankir, Mohammed K.
A1  - Seyfried, Florian
T1  - Impact of Excess Body Weight on Postsurgical Complications
JF  - Visceral Medicine
N2  - Background: Obesity is considered a risk factor for postoperative complications as it can limit exposure to the operation field, thereby significantly prolonging surgery time. Obesity-associated comorbidities, such as low-grade systemic inflammation, impaired functional status, and type 2 diabetes, are independent risk factors for impaired anastomotic wound healing and nonsurgical site infections. If obesity itself is an independent risk factor for surgical complications remains controversial, but the reason for this is largely unexplored. Summary: A MEDLINE literature search was performed using the terms: “obesity,” “excess body weight,” and “surgical complications.” Out of 65,493 articles 432 meta-analyses were screened, of which 25 meta-analyses were on the subject. The vast majority of complex oncologic procedures in the field of visceral surgery have shown higher complication rates in obese patients. Meta-analyses from the last 10 to 15 years with high numbers of patients enrolled consistently have shown longer operation times, higher blood loss, longer hospital stay for colorectal procedures, oncologic upper gastrointestinal (GI) procedures, and pancreatic surgery. Interestingly, these negative effects seem not to affect the overall survival in oncologic patients, especially in esophageal resections. A selection bias in oncologic upper GI patients may have influenced the results with higher BMI in upper GI cancer to be a predictor for better nutritional and performance status. Key Messages: Contrary to bariatric surgery, only limited evidence indicated that site and type of surgery, the approach to the abdominal cavity (laparoscopic vs. open), institutional factors, and the type of perioperative care such as ERAS protocols may play a role in determining postsurgical complications in obese patients. The initial question remains therefore partially unanswered. Large nationwide register-based studies are necessary to better understand which aspects of obesity and its related comorbidities define it as a risk factor for surgical complications.
KW  - obesity
KW  - surgical complications
KW  - laparoscopy
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-244890
SN  - 2297-4725
SN  - 2297-475X
VL  - 37
IS  - 4
ER  - 
TY  - THES
A1  - Schnell, Nadine
T1  - Ergebnisse nach Roux-Y-Magenbypass – eine Analyse von Prediktoren für das postoperative Outcome
T1  - Results after Roux-en-Y Gastric Bypass – Analysis of Predictors for the Postoperative Outcome
N2  - Die Adipositas mit ihren Begleiterkrankungen stellt weltweit ein progredientes Problem dar, für das es bis zum jetzigen Zeitpunkt keine langfristig effektive konservative Therapie gibt. Die einzige nachhaltig erfolgreiche Therapie besteht derzeit in der bariatrischen/metabolischen Chirurgie. Der Roux-Y-Magenbypass ist momentan eines der am häufigsten angewendeten chirurgischen Verfahren zur Therapie der Adipositas, welches zu einem dauerhaften Gewichtsverlust sowie simultaner Therapie der Begleiterkrankungen führt. Trotz der überzeugenden Therapieerfolge kommt es immer wieder zu Komplikationen bzw. einem mangelhaften Ansprechen (Non Responding) auf die Operation. Ziel der Studie war es, mithilfe eines Score-Systems schon präoperativ anhand von bestimmten Variablen das Risiko für ein schlechtes postoperatives Ergebnis bzw. ein Non Responding abzuschätzen. Auf diese Weise sollen in Zukunft mangelhafte Therapieergebnisse und postoperative Komplikationen vermieden bzw. die Nachsorge dementsprechend individuell angepasst werden.
N2  - Obesity and obesity-related comorbidities represent a progressive problem worldwide, for which there is currently no long-term effective conservative treatment. Actually, the only long-term successfull therapy is bariatric/metabolic surgery. The Roux-en-Y gastric bypass is currently one of the most frequently used surgical procedures for the treatment of obesity, which leads to permanent weight loss and simultaneous treatment of comorbidities. Despite the convincing therapeutic success, complications or a non-responding to the operation occur repeatedly. The aim of the study was to use a score system to estimate the risk of a poor postoperative result or non-responding preoperatively on the basis of certain variables. In this way, unsatisfactory therapy results and postoperative complications are to be avoided in the future and the follow-up care to be individually adapted accordingly.
KW  - roux y
KW  - Adipositas
KW  - Prediktoren
KW  - Outcome
KW  - Magenbypass
KW  - roux y Magenbypass
KW  - roux-en-y gastric bypass
KW  - obesity
KW  - Predictors
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-211848
ER  - 
TY  - JOUR
A1  - Bankoglu, Ezgi Eyluel
A1  - Arnold, Charlotte
A1  - Hering, Ilona
A1  - Hankir, Mohammed
A1  - Seyfried, Florian
A1  - Stopper, Helga
T1  - Decreased chromosomal damage in lymphocytes of obese patients after bariatric surgery
JF  - Scientific Reports
N2  - The number of bariatric surgeries being performed worldwide has markedly risen. While the improvement in obesity-associated comorbidities after bariatric surgery is well-established, very little is known about its impact on cancer risk. The peripheral lymphocyte micronucleus test is a widely used method for the monitoring of chromosomal damage levels in vivo, and micronucleus frequency positively correlates with cancer risk. Therefore, the aim of this study was to compare the micronucleus frequency before and after bariatric surgery in obese subjects. Peripheral blood mononuclear cells were collected from 45 obese subjects before and at two time-points after bariatric surgery (6 and 12 months) to assess spontaneous micronucleus frequency. Consistent with the increased cancer risk previously shown, bariatric surgery-induced weight loss led to a significant reduction in lymphocyte micronucleus frequency after 12 months. Interestingly, comorbidities such as type 2 diabetes mellitus and metabolic syndrome further seemed to have an impact on the lymphocyte micronucleus frequency. Our findings may indicate a successful reduction of cancer risk in patients following weight loss caused by bariatric surgery.
KW  - obesity
KW  - bariatric surgery
KW  - cancer risk
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-177090
VL  - 8
IS  - 11195
ER  -